Skip to main content
Erschienen in: Hepatology International 3/2013

01.07.2013 | Original Article

Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C

verfasst von: Li Kong, Kun Liu, Yu-Zhuo Zhang, Meng Jin, Bo-Rong Wu, Wei-Zhen Wang, Wei Li, Yue-Min Nan, Youhai H. Chen

Erschienen in: Hepatology International | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hepatitis C virus (HCV) infection causes chronic hepatitis in approximately 80 % of cases. Although it is well recognized that the immune system plays an important role in determining the outcomes of HCV infection, the underlying molecular mechanisms of persistent HCV infection and hepatic injury are incompletely understood. Tumor necrosis factor-α-induced protein 8-like 2 (TNFAIP8L2, TIPE2) is a newly identified negative regulator of innate and adaptive immunity. The goal of the present study is to investigate the potential role of TIPE2 in chronic hepatitis C (CHC) infection.

Methods

We used quantitative real-time reverse transcription polymerase chain reaction to examine the mRNA expression levels of TIPE2, Toll-like receptor (TLR) 2, and TLR4 in peripheral blood mononuclear cells from 60 CHC patients and 30 healthy controls.

Results

The TIPE2 mRNA expression was significantly downregulated, whereas that of TLR2 and TLR4 was upregulated in CHC patients compared with healthy controls. TIPE2 mRNA expression levels were negatively correlated with serum ALT, AST, and HCV RNA levels. TIPE2 mRNA expression was also negatively correlated with TLR2 and TLR4 mRNA levels in CHC patients. Moreover, TIPE2 mRNA expression was upregulated, whereas that of TLR2 and TLR4 was downregulated after treatment of patients with interferon-α and ribavirin.

Conclusions

These results indicate that HCV may promote chronic hepatitis by decreasing TIPE2 expression while enhancing TLR signaling.
Literatur
1.
Zurück zum Zitat Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20(1):1–16CrossRefPubMed Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20(1):1–16CrossRefPubMed
2.
Zurück zum Zitat Isaguliants MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol 2003;4(3):185–193CrossRefPubMed Isaguliants MG, Ozeretskovskaya NN. Host background factors contributing to hepatitis C virus clearance. Curr Pharm Biotechnol 2003;4(3):185–193CrossRefPubMed
3.
Zurück zum Zitat Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008;133(3):415–426CrossRefPubMed Sun H, Gong S, Carmody RJ, Hilliard A, Li L, Sun J, Kong L, Xu L, Hilliard B, Hu S, Shen H, Yang X, Chen YH. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. Cell 2008;133(3):415–426CrossRefPubMed
4.
Zurück zum Zitat Lou Y, Liu S. The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 2011;49(1–2):4–7CrossRefPubMed Lou Y, Liu S. The TIPE (TNFAIP8) family in inflammation, immunity, and cancer. Mol Immunol 2011;49(1–2):4–7CrossRefPubMed
5.
Zurück zum Zitat Li D, Song L, Fan Y, Li X, Li Y, Chen J, Zhu F, Guo C, Shi Y, Zhang L. Down regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133(3):422–427CrossRefPubMed Li D, Song L, Fan Y, Li X, Li Y, Chen J, Zhu F, Guo C, Shi Y, Zhang L. Down regulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Immunol 2009;133(3):422–427CrossRefPubMed
6.
Zurück zum Zitat Zhang S, Zhang Y, Wei X, Zhen J, Wang Z, Li M, Miao W, Ding H, Du P, Zhang W, He M, Yi F. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta 2010;1802(11):1078–1086CrossRefPubMed Zhang S, Zhang Y, Wei X, Zhen J, Wang Z, Li M, Miao W, Ding H, Du P, Zhang W, He M, Yi F. Expression and regulation of a novel identified TNFAIP8 family is associated with diabetic nephropathy. Biochim Biophys Acta 2010;1802(11):1078–1086CrossRefPubMed
7.
Zurück zum Zitat Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, Ma C, Gao C, Chen Y, Liu S. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammationin humans and mice. Mol Immunol 2011;48(9–10):1203–1208CrossRefPubMed Xi W, Hu Y, Liu Y, Zhang J, Wang L, Lou Y, Qu Z, Cui J, Zhang G, Liang X, Ma C, Gao C, Chen Y, Liu S. Roles of TIPE2 in hepatitis B virus-induced hepatic inflammationin humans and mice. Mol Immunol 2011;48(9–10):1203–1208CrossRefPubMed
8.
Zurück zum Zitat Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic ras. Mol Cell 2012;45(5):610–618CrossRefPubMed Gus-Brautbar Y, Johnson D, Zhang L, Sun H, Wang P, Zhang S, Zhang L, Chen YH. The anti-inflammatory TIPE2 is an inhibitor of the oncogenic ras. Mol Cell 2012;45(5):610–618CrossRefPubMed
9.
Zurück zum Zitat Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association. Guideline of prevention and treatment for hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi 2004;38(3):210–215 Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association. Guideline of prevention and treatment for hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi 2004;38(3):210–215
10.
Zurück zum Zitat Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological feature of hepatic injury and viral persistence. Hepatology 1999;30:595–601CrossRefPubMed Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological feature of hepatic injury and viral persistence. Hepatology 1999;30:595–601CrossRefPubMed
11.
Zurück zum Zitat Michalak TI. Immune cell reservoirs of persisting hepatitis C virus. Gut 2010;59(7):867–868CrossRefPubMed Michalak TI. Immune cell reservoirs of persisting hepatitis C virus. Gut 2010;59(7):867–868CrossRefPubMed
12.
Zurück zum Zitat Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008;134(3):812–822CrossRefPubMed Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, Michalak TI. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology 2008;134(3):812–822CrossRefPubMed
13.
Zurück zum Zitat Mozer-Lisewska I, Dworacki G, Kaczmarek E, Sluzewski W, Kaczmarek M, Woźniak A, Zeromski J. Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C—the role of dendritic cells. Scand J Immunol 2006;63(4):311–319CrossRefPubMed Mozer-Lisewska I, Dworacki G, Kaczmarek E, Sluzewski W, Kaczmarek M, Woźniak A, Zeromski J. Significance of alterations in PBMC immunophenotype of children with chronic viral hepatitis C—the role of dendritic cells. Scand J Immunol 2006;63(4):311–319CrossRefPubMed
14.
Zurück zum Zitat Stamataki Z. Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 2010;8(9):977–980CrossRefPubMed Stamataki Z. Hepatitis C infection of B lymphocytes: more tools to address pending questions. Expert Rev Anti Infect Ther 2010;8(9):977–980CrossRefPubMed
15.
Zurück zum Zitat Panasiuk A, Parfieniuk A, Zak J, Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2010;30(3):472–478CrossRefPubMed Panasiuk A, Parfieniuk A, Zak J, Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2010;30(3):472–478CrossRefPubMed
16.
Zurück zum Zitat Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008;12(3):675–692CrossRefPubMed Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008;12(3):675–692CrossRefPubMed
17.
Zurück zum Zitat Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4(11):622–634CrossRefPubMed Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol 2007;4(11):622–634CrossRefPubMed
18.
Zurück zum Zitat Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914–922CrossRefPubMed Broering R, Wu J, Meng Z, Hilgard P, Lu M, Trippler M, Szczeponek A, Gerken G, Schlaak JF. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008;48(6):914–922CrossRefPubMed
19.
Zurück zum Zitat Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol J 2012;9(1):126CrossRefPubMed Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol J 2012;9(1):126CrossRefPubMed
20.
Zurück zum Zitat Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011;204(5):793–801CrossRefPubMed Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, Tanaka T, Arai M, Fujiwara K, Saito K, Roger T, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 2011;204(5):793–801CrossRefPubMed
21.
Zurück zum Zitat Caramalho I, Rodrigues-Duarte L, Perez A, Zelenay S, Penha-Gonçalves C, Demengeot J. Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice. Scand J Immunol 2011;74(6):585–595CrossRefPubMed Caramalho I, Rodrigues-Duarte L, Perez A, Zelenay S, Penha-Gonçalves C, Demengeot J. Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice. Scand J Immunol 2011;74(6):585–595CrossRefPubMed
22.
Zurück zum Zitat Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, Li Y, Wang PZ, Bai XF. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010;118(4):261–270CrossRefPubMed Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, Li Y, Wang PZ, Bai XF. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS 2010;118(4):261–270CrossRefPubMed
23.
Zurück zum Zitat Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S. Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(10):1627–1632CrossRefPubMed Sato K, Ishikawa T, Okumura A, Yamauchi T, Sato S, Ayada M, Matsumoto E, Hotta N, Oohashi T, Fukuzawa Y, Kakumu S. Expression of toll-like receptors in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(10):1627–1632CrossRefPubMed
24.
Zurück zum Zitat Salem ML, El-Demellawy M, El-Azm AR. The potential use of toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 2010;262(2):96–104CrossRefPubMed Salem ML, El-Demellawy M, El-Azm AR. The potential use of toll-like receptor agonists to restore the dysfunctional immunity induced by hepatitis C virus. Cell Immunol 2010;262(2):96–104CrossRefPubMed
25.
Zurück zum Zitat Yakushijin T, Kanto T, Inoue M, Oze T, Miyazaki M, Itose I, Miyatake H, Sakakibara M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced expression and functional impairment of toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006;34(3):156–162CrossRefPubMed Yakushijin T, Kanto T, Inoue M, Oze T, Miyazaki M, Itose I, Miyatake H, Sakakibara M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Reduced expression and functional impairment of toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006;34(3):156–162CrossRefPubMed
26.
Zurück zum Zitat Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17(9):2619–2627CrossRefPubMed Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, Sanmamed MF, Le Bon A, Melero I. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 2011;17(9):2619–2627CrossRefPubMed
27.
Zurück zum Zitat Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J 2010;7:265CrossRefPubMed Poat B, Hazari S, Chandra PK, Gunduz F, Alvarez X, Balart LA, Garry RF, Dash S. Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication. Virol J 2010;7:265CrossRefPubMed
28.
Zurück zum Zitat Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 2012;189(6):2768–2773CrossRefPubMed Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y, Chen YH. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 2012;189(6):2768–2773CrossRefPubMed
Metadaten
Titel
Downregulation of TIPE2 mRNA expression in peripheral blood mononuclear cells from patients with chronic hepatitis C
verfasst von
Li Kong
Kun Liu
Yu-Zhuo Zhang
Meng Jin
Bo-Rong Wu
Wei-Zhen Wang
Wei Li
Yue-Min Nan
Youhai H. Chen
Publikationsdatum
01.07.2013
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 3/2013
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-013-9435-2

Weitere Artikel der Ausgabe 3/2013

Hepatology International 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.